Abstract:Recent evolution in drug repurposing has brought new anticipation, especially in the conflict against neurodegenerative diseases (NDDs). The traditional approach to developing novel drugs for these complex disorders is laborious, time-consuming, and often abortive. However, drug reprofiling which is the implementation of illuminating novel therapeutic applications of existing approved drugs, has shown potential as a promising strategy to accelerate the hunt for therapeutics. The advancement of computational approaches and artificial intelligence has expedited drug repurposing. These progressive technologies have enabled scientists to analyse extensive datasets and predict potential drug-disease interactions. By prospecting into the existing pharmacological knowledge, scientists can recognise potential therapeutic candidates for reprofiling, saving precious time and resources. Preclinical models have also played a pivotal role in this field, confirming the effectiveness and mechanisms of action of repurposed drugs. Several studies have occurred in recent years, including the discovery of available drugs that demonstrate significant protective effects in NDDs, relieve debilitating symptoms, or slow down the progression of the disease. These findings highlight the potential of repurposed drugs to change the landscape of NDD treatment. Here, we present an overview of recent developments and major advances in drug repurposing intending to provide an in-depth analysis of traditional drug discovery and the strategies, approaches and technologies that have contributed to drug repositioning. In addition, this chapter attempts to highlight successful case studies of drug repositioning in various therapeutic areas related to NDDs and explore the clinical trials, challenges and limitations faced by researchers in the field. Finally, the importance of drug repositioning in drug discovery and development and its potential to address discontented medical needs is also highlighted.

Can old drugs learn new tricks? Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

New government drug repurposing programs: Opportunities and uncertainties

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

Drug Repurposing: A Leading Strategy for New Threats and Targets

Repurposing of Drugs: Updates and New Perspectives

Repurposing – second life for drugs

Drug Repurposing: Far Beyond New Targets for Old Drugs

Drug repurposing: progress, challenges and recommendations

The Medicines Repurposing Program – a critical perspective

New clinical insight in amyotrophic lateral sclerosis and innovative clinical development from the non-profit repurposing trial of the old drug guanabenz

Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.

How drug repurposing can advance drug discovery: challenges and opportunities

Regulatory considerations and intellectual property rights of repurposed drugs

Reimagining old drugs with new tricks: Mechanisms, strategies and notable success stories in drug repurposing for neurological diseases

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Overcoming cancer therapeutic bottleneck by drug repurposing

Drug discovery and development: the role of artificial intelligence in drug repurposing

Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives

Approaches of pre-clinical and clinical trials of repurposed drug